<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  2     DOSAGE AND ADMINISTRATION<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           Recommended Dose: Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily. Resistant or intolerant Ph+ CML-CP and CML-AP: 400 mg orally twice daily. (2.1)<BR><BR>                           <BR>                           Administer Tasigna approximately 12 hours apart and must not take with food. (2.1)<BR><BR>                           <BR>                           Swallow the capsules whole with water. Do not consume food for at least 2 hours before the dose is taken and for at least one hour after. (2.1)<BR><BR>                           <BR>                           Dose adjustment may be required for hematologic and non-hematologic toxicities, and drug interactions. (2.2)<BR><BR>                           <BR>                           A lower starting dose is recommended in patients with hepatic impairment (at baseline). (2.2)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1     Recommended Dosing<BR>                     <BR>                        Tasigna should be taken twice daily at approximately 12 hour intervals and must not be taken with food. The capsules should be swallowed whole with water. No food should be consumed for at least 2 hours before the dose is taken and no food should be consumed for at least one hour after the dose is taken [<BR>                           s<BR>                           ee <BR>                           Box<BR>                           ed<BR>                            Warning, Warnings and Precautions (5.<BR>                           8<BR>                           ), <BR>                           Clinical Pharmacology<BR>                            <BR>                           (<BR>                           12.<BR>                           3<BR>                           )<BR>                           ].<BR>                        For patients who are unable to swallow capsules, the contents of each capsule may be dispersed in one teaspoon of applesauce (puréed apple). The mixture should be taken immediately (within 15 minutes) and should not be stored for future use [<BR>                           s<BR>                           ee Clinical Pharmacology (12.3)].<BR>                        Tasigna may be given in combination with hematopoietic growth factors such as erythropoietin or G-CSF if clinically indicated. Tasigna may be given with hydroxyurea or anagrelide if clinically indicated.<BR>                        <BR>                           Newly Diagnosed Ph+ CML-CP<BR>                        <BR>                        The recommended dose of Tasigna is 300 mg orally twice daily [see Clinical Pharmacology (12.3)]. <BR>                        <BR>                           Resistant or Intolerant Ph+ CML-CP and CML-AP<BR>                        <BR>                        The recommended dose of Tasigna (nilotinib) is 400 mg orally twice daily [see Clinical Pharmacology (12.3)].<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.2     Dose Adjustments or Modifications<BR>                     <BR>                        <BR>                           QT interval prolongation: <BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 1:&#160;Dose Adjustments for QT Prolongation</caption><BR>                           <col width="163"/><BR>                           <col width="552"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Toprule Lrule "/><BR>                                 <td styleCode="Toprule Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule ">ECGs with a QTc<br/>&gt;480 msec<br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                 </td><BR>                                 <td styleCode="Lrule Rrule ">1. Withhold Tasigna, and perform an analysis of serum potassium and magnesium, and if below lower limit of normal, correct with supplements to within normal limits. Concomitant medication usage must be reviewed.<br/>2. Resume within 2 weeks at prior dose if QTcF returns to &lt;450&#160;msec and to within 20 msec of baseline.<br/>3. If QTcF is between 450 msec and 480 msec after 2 weeks, reduce the dose to 400 mg once daily.<br/>4. If, following dose-reduction to 400 mg once daily, QTcF returns to &gt;480 msec, Tasigna should be discontinued.<br/>5. An ECG should be repeated approximately 7 days after any dose adjustment.</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           Myelosuppression <BR>                        Tasigna may need to be withheld and/or dose reduced for hematological toxicities (neutropenia, thrombocytopenia) that are not related to underlying leukemia (Table 2).<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 2:&#160;Dose Adjustments for Neutropenia and Thrombocytopenia</caption><BR>                           <col width="163"/><BR>                           <col width="204"/><BR>                           <col width="348"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Toprule Lrule "/><BR>                                 <td styleCode="Toprule "/><BR>                                 <td styleCode="Toprule Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule ">Newly diagnosed Ph+ CML in chronic phase at 300 mg twice daily<br/><BR>                                    <br/><BR>                                    <br/>Resistant or intolerant&#160;Ph+ CML in&#160;chronic phase or accelerated phase at 400 mg twice daily</td><BR>                                 <td styleCode="Lrule Rrule ">ANC* &lt;1.0 x 10<sup>9</sup>/L and/or platelet counts&#160;&lt;50 x 10<sup>9</sup>/L<br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                 </td><BR>                                 <td styleCode="Lrule Rrule ">1. Stop Tasigna, and monitor blood counts<br/>2. Resume within 2 weeks at prior dose if ANC &gt;1.0 x 10<sup>9</sup>/L and platelets &gt;50 x 10<sup>9</sup>/L<br/>3. If blood counts remain low for &gt;2 weeks, reduce the dose to 400 mg once daily<br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>*ANC = absolute neutrophil count<BR>                        See Table 3 for dose adjustments for elevations of lipase, amylase, bilirubin, and/or hepatic transaminases [<BR>                           s<BR>                           ee Adverse <BR>                           R<BR>                           eactions (6.1)]<BR>                           .<BR>                        <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 3:&#160;Dose Adjustments for Selected Non-hematologic Laboratory Abnormalities</caption><BR>                           <col width="139"/><BR>                           <col width="594"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Toprule Lrule "/><BR>                                 <td styleCode="Toprule Rrule "/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule ">Elevated serum lipase or amylase&#160;&#8805;Grade 3</td><BR>                                 <td styleCode="Lrule Rrule ">1. Withhold Tasigna, and monitor serum lipase or amylase<br/>2. Resume treatment at 400 mg once daily if serum lipase or amylase returns to &#8804;Grade 1</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule Lrule Rrule ">Elevated bilirubin &#8805;Grade 3</td><BR>                                 <td styleCode="Toprule Lrule Rrule ">1. Withhold Tasigna, and monitor bilirubin<br/>2. Resume treatment at 400 mg once daily if bilirubin returns to &#8804;Grade 1</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule Lrule Rrule ">Elevated hepatic transaminases<br/>&#8805;Grade 3</td><BR>                                 <td styleCode="Toprule Lrule Rrule ">1. Withhold Tasigna, and monitor hepatic transaminases<br/>2. Resume treatment at 400 mg once daily if hepatic transaminases returns to &#8804;Grade 1</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           Other Non-hematologic Toxicities <BR>                        If other clinically significant moderate or severe non-hematologic toxicity develops, withhold dosing, and resume at 400 mg once daily when the toxicity has resolved. If clinically appropriate, escalation of the dose back to 300 mg (newly diagnosed Ph+ CML-CP) or 400 mg (resistant or intolerant Ph+ CML-CP and CML-AP) twice daily should be considered. For Grade 3 to 4 lipase elevations, dosing should be withheld, and may be resumed at 400 mg once daily. Test serum lipase levels monthly or as clinically indicated. For Grade 3 to 4 bilirubin or hepatic transaminase elevations, dosing should be withheld, and may be resumed at 400 mg once daily. Test bilirubin and hepatic transaminases levels monthly or as clinically indicated [<BR>                           s<BR>                           ee Warnings and Precautions (5<BR>                           .4, 5.5<BR>                           )<BR>                           ,<BR>                            Use in Specific Populations (8<BR>                           .7<BR>                           )].<BR>                        <BR>                        <BR>                           Hepatic Impairment <BR>                        If possible, consider alternative therapies. If Tasigna must be administered to patients with hepatic impairment, consider the following dose reduction:<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <caption>Table 4: Dose Adjustments for Hepatic Impairment (At Baseline)</caption><BR>                           <col width="217"/><BR>                           <col width="194"/><BR>                           <col width="275"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Toprule Lrule Rrule ">Newly diagnosed Ph+ CML in chronic phase at 300 mg twice daily</td><BR>                                 <td styleCode="Toprule Lrule Rrule ">Mild, Moderate or Severe*</td><BR>                                 <td styleCode="Toprule Lrule Rrule ">An initial dosing regimen of 200 mg twice daily followed by dose escalation to 300 mg twice daily based on tolerability</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Toprule Lrule Rrule "><BR>                                    <br/><BR>                                    <br/><BR>                                    <br/>Resistant or intolerant Ph+ CML in chronic phase or accelerated phase at 400 mg twice daily</td><BR>                                 <td styleCode="Toprule Lrule Rrule ">Mild or Moderate*</td><BR>                                 <td styleCode="Toprule Lrule Rrule ">An initial dosing regimen of 300 mg twice daily followed by dose escalation to 400 mg twice daily based on tolerability</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule "/><BR>                                 <td styleCode="Toprule Lrule Rrule ">Severe*</td><BR>                                 <td styleCode="Toprule Lrule Rrule ">A starting dose of 200 mg twice daily followed by a sequential dose escalation to 300 mg twice daily and then to 400 mg twice daily based on tolerability</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>* Mild = mild hepatic impairment (Child-Pugh Class A); Moderate = moderate hepatic impairment (Child-Pugh Class B); Severe = severe hepatic impairment (Child-Pugh Class C) [see Warnings and Precautions (5.9), Use in Specific Populations (8.7)].<BR>                        <BR>                           Concomitant Strong CYP3A4 Inhibitors <BR>                        Avoid the concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole). Grapefruit products may also increase serum concentrations of nilotinib and should be avoided. Should treatment with any of these agents be required, it is recommended that therapy with Tasigna be interrupted. If patients must be co-administered a strong CYP3A4 inhibitor, based on pharmacokinetic studies, consider a dose reduction to 300 mg once daily in patients with resistant or intolerant Ph+ CML or to 200 mg once daily in patients with newly diagnosed Ph+ CML-CP. However, there are no clinical data with this dose adjustment in patients receiving strong CYP3A4 inhibitors. If the strong inhibitor is discontinued, a washout period should be allowed before the Tasigna dose is adjusted upward to the indicated dose. Close monitoring for prolongation of the QT interval is indicated for patients who cannot avoid strong CYP3A4 inhibitors [<BR>                           s<BR>                           ee<BR>                            Boxed Warning, Warnings and Precautions<BR>                            <BR>                           (5.<BR>                           2<BR>                           ,<BR>                            5.7<BR>                           )<BR>                           ,<BR>                            Drug Interactions (7.<BR>                           2<BR>                           )].<BR>                        <BR>                           Concomitant Strong CYP3A4 Inducers <BR>                        Avoid the concomitant use of strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital). Patients should also refrain from taking St. John’s Wort. Based on the nonlinear pharmacokinetic profile of nilotinib, increasing the dose of Tasigna when co-administered with such agents is unlikely to compensate for the loss of exposure [<BR>                           s<BR>                           ee Drug Interactions (7.<BR>                           2<BR>                           )]<BR>                           .<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>